Toll free: 1-855 542-5672 (1-855-KICK-MSA)

Donate Now
Donate Now

REFERENCES

  1. Sun Z, Jia D, Shi Y, et al. Prediction of orthostatic hypotension in multiple system atrophy and Parkinson disease. Sci Rep. 2016;6:21649.
  2. Eschlböck, S., Wenning, G. & Fanciulli, A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm124, 1567–1605 (2017).
  3. Palma JA, Norcliffe-Kaufmann L, Kaufmann H. An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease. Mov Disord. 2016;31(4):598–600.
  4. Tanaka K, et al. Compression stocking length effects on arterial blood pressure and heart rate following head-up tilt in healthy volunteers. Nursing Research. 2014;63(6):435–438.
  5. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology. 2016; 87(12):1274–1280.
  6. Rembold CM. Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases. Am J Med. 2018;131(4):444-446.
  7. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleve Clin J Med. 2010;77(5):298–306.
  8. Wieling, W., van, Dijk, N., Thijs, R.D., de, Lange, F.J., Krediet, C.T.P. and Halliwill, J.R. (2015), Physical countermeasures to increase orthostatic tolerance. J Intern Med, 277: 69-82.
  9. Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension. J Am Heart Assoc. 2017; 6(10).
  10. Parsaik AK, Singh B, Altayar O, et al. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013;28(11):1496–1503.
  11. Pérez-Lloret S, et al. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases, Expert Opinion on Pharmacotherapy. 2019;(20)6:635-645.
  12. Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018;91(16):e1539–e1544.
  13. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Archives of neurology. 2006; 63(4):513–518.
  14. Shibao C, Martinez J, Palma JA, Kaufmann H, Biaggioni I. Norepinephrine levels predicts the improvement in orthostatic symptoms after atomoxetine in patients with neurogenic orthostatic hypotension (P5.320). Neurology. 2017; 88(16 Supplement).
  15. Raccagni, C. et al. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. Parkinsonism & Related Disorders. 2019; 67:60 – 65.
  16. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson’s disease. N Engl J Med2012;366:511–519
  17. Meissner, Wassilios G. et al.Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature. Parkinsonism & Related Disorders. 2016. 24:69 – 75.
  18. Wang L, Xiong N, Huang J, et al. Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson’s Disease. Front Aging Neurosci. 2017;9:206.
  19. Constantinescu, R., Richard, I. and Kurlan, R. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Mov. Disord. 2007. 22: 2141-2148.
  20. Friess, Elisabeth et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism & Related Disorders. 2006; 12(7):432 – 437.
  21. Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;72(3):300–303.
  22. Dressler, D., Altenmueller, E., Bhidayasiri, R. et al.Strategies for treatment of dystonia. J Neural Transm 123, 251–258 (2016).
  23. Jain, S., Dawson, J., Quinn, N.P. and Playford, E.D. (2004), Occupational therapy in multiple system atrophy: A pilot randomized controlled trial. Mov. Disord., 19: 1360-1364.
  24. Müller, J., Wissel, J., Masuhr, F. et al.Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol 248, 478–482 (2001).
  25. Smania N, Corato E, Tinazzi M, Montagnana B, Fiaschi A, Aglioti SM. The effect of two different rehabilitation treatments in cervical dystonia: preliminary results in four patients. Funct Neurol 2003;18:219–225.
  26. Müller, J., Wenning, G., Wissel, J. et al.Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249, 300–304 (2002).
  27. Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation?. J Neurol Neurosurg Psychiatry. 2000;68(1):65–69.
  28. Perez-Lloret S, Flabeau O, Fernagut PO, et al. Current Concepts in the Treatment of Multiple System Atrophy. Mov Disord Clin Pract. 2015;2(1):6–16.
  29. Yu Y, de Groat WC. Nitric oxide modulates bladder afferent nerve activity in the in vitro urinary bladder-pelvic nerve preparation from rats with cyclophosphamide induced cystitis. Brain Res. 2013;1490:83–94.
  30. St Louis EK, Boeve BF. REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clin Proc. 2017;92(11):1723–1736.
  31. Videnovic A. Management of sleep disorders in Parkinson’s disease and multiple system atrophy. Mov Disord. 2017;32(5):659–668.
  32. Du JJ, Wang T, Huang P, et al. Clinical characteristics and quality of life in Chinese patients with multiple system atrophy. Brain Behav. 2018;8(12):e01135.
  33. Segev-Jacubovski O, Herman T, Yogev-Seligmann G, Mirelman A, Giladi N, Hausdorff JM. The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk?. Expert Rev Neurother. 2011;11(7):1057–1075.
  34. da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018;13(2):e0193113.
  35. Boggio, P.S., et al. (2005), Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov. Disord., 20: 1178-1184.
  36. Cortelli P, Calandra-Buonaura G, Benarroch EE, et al. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630–639.
  37. Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol. 2007;9(5):347–353.
  38. Ghorayeb I, et al. Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Medicine. 2005;6(4):359-362.
  39. Coon EA, Ahlskog JE, Silber MH, et al. Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?. Parkinsonism Relat Disord. 2018;48:51–53.
  40. You HY, Wu L, Yang HT, Yang C, Ding XL. A Comparison of Pain between Parkinson’s Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey. Pain Res Manag. 2019;2019:3150306.
  41. Pani G. Neuroprotective effects of dietary restriction: Evidence and mechanisms. Semin Cell Dev Biol. 2015;40:106-14.
  42. Alcalay, R.N., Gu, Y., Mejia‐Santana, H., Cote, L., Marder, K.S. and Scarmeas, N. (2012), The association between Mediterranean diet adherence and Parkinson’s disease. Mov. Disord., 27: 771-774.
  43. Maswood N, Young J, Tilmont E, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004;101(52):18171–18176.
  44. Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A, Unni VK. Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice. PLoS One. 2015;10(6):e0128510.
  45. Molsberry, Samantha. 2019. Diet, Metabolomics, and Parkinson’s Disease. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. https://dash.harvard.edu/handle/1/42029734
  46. Du, Juanjuan et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Parkinsonism & Related Disorders. 2018;57:58 – 62.
  47. Kasai T, Tokuda T, Ohmichi T, et al. Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS One. 2016;11(1):e0147574.

JOIN THE MOVEMENT TO #DEFEATMSA

SUBSCRIBE TO OUR NEWSLETTER

Follow us on social media

Twitter Facebook Instagram Youtube Linkedin

About Us

Downloadables

Overview MSA Treatment (EN)

Overview MSA Treatment (SP)

Supporters

Get Involved


DEFEAT MSA ALLIANCE (USA) CONTACT INFORMATION:

29924 JEFFERSON AVENUE, SAINT CLAIR SHORES, MICHIGAN, 48082  USA
TOLL FREE NUMBER:  (855) 542-5672  (855 KICK-MSA)
INFO@DEFEATMSA.ORG

Copyright: ©2023-2024; Defeat MSA Alliance, All rights reserved. The brand names “Defeat MSA” and “Defeat Multiple System Atrophy” are trademarked and wholly owned by Defeat MSA Alliance. No part of this website may be copied without the express permission of Defeat MSA Alliance. For information, contact the trademark and copyright holder: copyright@defeatmsa.org

Privacy Policy

Translate »
Donate Now